FG-3175 / FibroGen - LARVOL DELTA

FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen’s Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO in Upcoming Clinical Trials (GlobeNewswire) - "FibroGen...announced a clinical trial supply agreement with Regeneron Pharmaceuticals to evaluate FibroGen’s immuno-oncology assets, FG-3165 and FG-3175, in combination with Regeneron’s anti-PD-1 therapy, LIBTAYO (cemiplimab), in patients with solid tumors....Under the clinical study collaboration and supply agreement, Regeneron will provide drug supply to FibroGen, who will be the sponsor of each Phase 1 monotherapy and combination trial....FibroGen to evaluate FG-3165...as monotherapy treatment as well as in combination with LIBTAYO in patients with select solid tumors. FibroGen to evaluate FG-3175...as monotherapy treatment as well as in combination with LIBTAYO in patients with select solid tumors."

Licensing / partnership • Solid Tumor

FibroGen Reports First Quarter 2024 Financial Results (GlobeNewswire) - "Upcoming Milestones:...Oncology Pipeline: (i) Anticipate initiation of Phase 2 monotherapy dose optimization study of FG-3246 in mCRPC in 2H 2024; (ii) Anticipate filing of an IND for FG-3175 (anti-CCR8 mAb) in 2025."

New P2 trial • Metastatic Castration-Resistant Prostate Cancer

FibroGen Reports Third Quarter 2023 Financial Results (GlobeNewswire) - "Upcoming Milestones: (i) Expect topline clinical trial results from Phase 1 monotherapy trial of FG-3246, a first-in-class antibody-drug conjugate (ADC) targeting a novel epitope on CD46 for metastatic castration-resistant prostate cancer (mCRPC) by 1Q 2024; (ii) Anticipate the initiation of a Phase 2 trial of FG-3246 for mCRPC in 2H 2024; (iii) Anticipate the filing of two INDs: FG-3165 (anti-Gal9 antibody) in 1Q 2024 and FG-3175 (anti-CCR8 antibody) in 2H 2024."

IND • New P2 trial • P1 data • Prostate Cancer

FibroGen Reports Second Quarter 2023 Financial Results (GlobeNewswire) - "Early-Stage Oncology Pipeline: (i) Anticipate the initiation of a Phase 2 trial of FG-3246, a first-in-class ADC targeting a novel epitope on CD46 for mCRPC in 2H 2024; (ii) Anticipate the filing of two INDs: FG-3165 (anti-Gal9 antibody) in 1Q 2024 and FG-3175 (anti-CCR8 antibody) in 2H 2024."

IND • New P2 trial • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor